Atsuko Ashida

Atsuko Ashida

Auto-generated profile, based on publicly available information

Atsuko Ashida

Center for Clinical Research Shinshu University Hospital Matsumoto Japan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2009 in Cancer Research
Verified
Journal Article
Open access
PDF file
MYMaki Yamaura
Maki Yamaura
JMJunji Mitsushita
Junji Mitsushita
SFShuichi Furuta
Shuichi Furuta
YKYukiko Kiniwa
Yukiko Kiniwa
AAAtsuko Ashida
Atsuko Ashida
TKTohru Kamata
Tohru Kamata
Generation of reactive oxygen species (ROS) has been implicated in carcinogenic development of melanoma, but the underlying molecular mechanism has not been fully elucidated. We studied the expression and function of the superoxide-generating NADPH oxidase (Nox)4 in human melanoma cells. Nox4 was up-regulated in 13 of 20 melanoma cell lines tested. Silencing of Nox4 expression in melanoma MM-BP cells by small interfering RNAs decreased ROS production and thereby inhibited anchorage-independent cell growth and tumorigenecity in nude mice. Consistently, a general Nox inhibitor, diphenylene iodonium, and antioxidants vitamine E and pyrrolidine dithiocarbamate blocked cell proliferation of MM-BP cells. Flow cytometric analysis indicated that Nox4 small interfering RNAs and diphenylene iodonium induced G2-M cell cycle arrest, which was also observed with another melanoma cell line, 928mel. This was accompanied by induction of the Tyr-15 phosphorylated, inactive form of cyclin-dependent kinase 1 (a hallmark of G2-M checkpoint) and hyperphosphorylation of cdc25c leading to its increased binding to 14-3-3 proteins. Ectopic expression of catalase, a scavenger of ROS, also caused accumulation of cells in G2-M phase. Immunohistochemistry revealed that expression of Nox4 was detected in 31.0% of 13 melanoma patients samples, suggesting the association of Nox4 expression with some steps of melanoma development. The findings suggest that Nox4-generated ROS are required for transformation phenotype of melanoma cells and contribute to melanoma growth through regulation of G2-M cell cycle progression. [Cancer Res 2009;69(6):2647–54]

23 December 2022 in Experimental Dermatology
Verified
Journal Article
Closed access
AAAtsuko Ashida
Atsuko Ashida
STShuta Tomida
Shuta Tomida
TITokuro Iwabuchi
Tokuro Iwabuchi
YSYuki Sato
Yuki Sato
YKYukiko Kiniwa
Yukiko Kiniwa
RORyuhei Okuyama
Ryuhei Okuyama

1 January 2019 in Skin Cancer
Verified
Journal Article
Closed access
PDF file
KNKenta Nakamura
Kenta Nakamura
AAAtsuko Ashida
Atsuko Ashida
RNReina Nakamura
Reina Nakamura
YKYukiko Kiniwa
Yukiko Kiniwa
RORyuhei Okuyama
Ryuhei Okuyama
BRAF変異陰性の切除不能メラノーマの治療として,免疫チェックポイント阻害薬の抗PD-1/PD-L1抗体や抗CTLA-4抗体が選択されるが,それぞれの奏効率は30%と10%程度であり,過剰な自己免疫による副作用で治療継続が困難になる症例もある。今回,私たちは,そのような症例で,第三選択としてダカルバジンを使用したメラノーマの3症例を報告する。治療効果は,部分奏功1例,不変1例,進行1例であった。また,これらの3症例では,ダカルバジンの治療効果と血中のLDHや5-S-CDの値の変動が相関した。今後,症例を集積し,第三選択としてのダカルバジンの奏効率を報告し,治療効果を判定するマーカーとしてLDHや5-S-CDが有用であるか検討することが,メラノーマの治療選択に重要であると考える。